[1]陶 蕾,张宏江,范中阳.利拉鲁肽联合胰岛素治疗肥胖2型糖尿病的疗效[J].医学信息,2021,34(23):99-101.[doi:10.3969/j.issn.1006-1959.2021.23.028]
　TAO Lei,ZHANG Hong-jiang,FAN Zhong-yang.Effect of Liraglutide Combined with Insulin in the Treatment of Obesity Type 2 Diabetes Mellitus[J].Medical Information,2021,34(23):99-101.[doi:10.3969/j.issn.1006-1959.2021.23.028]
点击复制

利拉鲁肽联合胰岛素治疗肥胖2型糖尿病的疗效()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年23期
页码:
99-101
栏目:
论著
出版日期:
2021-12-01

文章信息/Info

Title:
Effect of Liraglutide Combined with Insulin in the Treatment of Obesity Type 2 Diabetes Mellitus
文章编号:
1006-1959（2021）23-0099-03
作者:
陶 蕾; 张宏江; 范中阳
（天津市西青医院药剂科1，老年病科2，天津 300380）
Author(s):
TAO Lei; ZHANG Hong-jiang; FAN Zhong-yang
(Department of Pharmacy1,Department of Geriatrics2,Tianjin Xiqing Hospital,Tianjin 300380,China)
关键词:
胰岛素; 肥胖; 2型糖尿病; 利拉鲁肽
Keywords:
Insulin; Obesity; Type 2 diabetes mellitus; Liraglutide
分类号:
R587.1
DOI:
10.3969/j.issn.1006-1959.2021.23.028
文献标志码:
A
摘要:
目的 观察胰岛素治疗的肥胖2型糖尿病患者联合应用利拉鲁肽的临床疗效。方法 选取2020年1月-2021年1月在我院诊治的60例胰岛素治疗的肥胖2型糖尿病患者为研究对象，采用随机数字表法分为对照组和观察组，各30例。对照组继续给予胰岛素治疗，观察组在对照组的基础上给予利拉鲁肽治疗，比较两组血糖指标、体质量指数、胰岛素日用量、血脂指标以及临床不良反应情况。结果 治疗后，两组FBG、2hPBG、HbA1c均低于治疗前，且观察组低于对照组，差异有统计学意义（P＜0.05）；治疗后，观察组体质量指数、胰岛素日用量均小于治疗前，对照组胰岛素日用量高于治疗前，且观察组体质量指数、胰岛素日用量均小于对照组，差异有统计学意义（P＜0.05）；治疗后，两组TC、TG、LDL-C均低于治疗前，且观察组低于对照组，差异有统计学意义（P＜0.05）；观察组不良反应发生率为6.67%，低于对照组的23.33%，差异有统计学意义（P＜0.05）。结论 利拉鲁肽联合胰岛素治疗肥胖2型糖尿病，可促进血糖水平控制，降低体质量指数，减少胰岛素日用量，降低血脂指标，且可降低不良反应发生率，提高治疗安全性。
Abstract:
Objective To observe the clinical effect of insulin combined with liraglutide in the treatment of obesity type 2 diabetes mellitus.Methods A total of 60 patients with obesity type 2 diabetes mellitus treated with insulin in our hospital from January 2020 to January 2021 were selected as the research objects. They were divided into control group and observation group by random number table method, with 30 cases in each group. The control group was treated with insulin, and the observation group was treated with liraglutide on the basis of the control group. The blood glucose index, body mass index, daily dosage of insulin, blood lipid index and clinical adverse reactions were compared between the two groups.Results After treatment, FBG, 2hPBG and HbA1c in the two groups were lower than those before treatment, and those in the observation group were lower than the control group, the differences were statistically significant (P<0.05). After treatment, the body mass index and daily insulin dosage of the observation group were lower than those before treatment, and the daily insulin dosage of the control group was higher than that before treatment, and the body mass index and daily insulin dosage of the observation group were lower than those of the control group, the difference was statistically significant (P<0.05). After treatment, TC, TG and LDL-C in the two groups were lower than those before treatment, and those in the observation group were lower than the control group, the differences were statistically significant (P<0.05) . The incidence of adverse reactions in the observation group was 6.67%, which was lower than 23.33% in the control group, and the difference was statistically significant (P<0.05).Conclusion Insulin combined with liraglutide in the treatment of obesity type 2 diabetes mellitus can control the blood glucose level, reduce body mass index, daily dosage of insulin, blood lipid indexes and the incidence of adverse reactions, and improve the safety of treatment.

参考文献/References:

[1]高会敏,尚勇.利拉鲁肽和格列美脲治疗2型糖尿病的效果及其安全性比较[J].医学综述,2016,22(13):2696-2698.[2]蒙光义,王冬晓,庞家莲,等.利拉鲁肽联合二甲双胍治疗2型糖尿病的疗效观察[J].中国药房,2015,26(5):658-660.[3]胥娟,黄文龙,唐伟,等.利拉鲁肽对新诊断２型糖尿病患者血清microRNA表达谱的影响[J].中国糖尿病杂志,2016,24(12):1082-1086.[4]施劭锋,陈根本,柯涓,等.利拉鲁肽联合甘精胰岛素对新诊断２型糖尿病的疗效观察[J].重庆医学,2017,46(20):2770-2773.[5]崔克勤,王海燕,唐键,等.利拉鲁肽单药治疗新诊超重或肥胖２型糖尿病的效果及安全性观察[J].山东医药,2016,56(30):47-49.[6]郭阳阳,陶晓燕,潘天荣,等.利拉鲁肽对超重及肥胖２型糖尿病患者体质量和胰岛素抵抗的影响[J].安徽医学,2017,38(2):162-165.[7]蒙光义,彭评志,庞家莲,等.利拉鲁肽联合二甲双胍治疗２型糖尿病临床疗效和安全性评估[J].医学综述,2015,21(17):3223-3226.[8]魏春燕,吴斌,苏娜,等.利拉鲁肽降低超重和肥胖患者体质量有效性和安全性的系统评价[J].中国药房,2016,27(21):2941-2944.[9]杨帆,李钶,蒋晓岚,等.利拉鲁肽对肥胖2型糖尿病合并非酒精性脂肪肝患者的肝脏脂肪沉积的影响研究[J].重庆医学,2016,45(25):3493-3495.[10]崔克勤,王海燕,唐键,等.利拉鲁肽单药治疗新诊超重或肥胖2型糖尿病的效果及安全性观察[J].山东医药,2016,56(30):47-49.[11]安欣,孙媛媛.利拉鲁肽治疗肥胖2型糖尿病合并高脂血症的临床观察[J].陕西医学杂志,2015(8):1084-1085.[12]王颖,高健康.利拉鲁肽联合胰岛素治疗非肥胖2型糖尿病患者的效果观察[J].基层医学论坛,2016,20(21):2904-2905.[13]王薇,王露,郭丹,等.利拉鲁肽对肥胖2型糖尿病患者MDA、GSH-Px水平的影响[J].中国医科大学学报,2015,44(1):84-86.[14]李意,赵蕾,祝开思,等.胰岛素治疗超重或肥胖２型糖尿病患者加用利拉鲁肽的临床疗效观察[J].中国糖尿病杂志,2015,23(3):241-244.[15]张洁,赵媛媛,周慧敏,等.利拉鲁肽对血糖控制不佳的2型糖尿病患者胰岛β细胞功能及血糖波动的影响[J].中国糖尿病杂志,2015,23(6):527-529.

相似文献/References:

[1]龙 颖,李运泽,汤中敏,等.非酒精性脂肪性肝病与血尿酸水平测定及其临床意义[J].医学信息,2018,31(07):92.[doi:10.3969/j.issn.1006-1959.2018.07.029]
　LONG Ying,LI Yun-ze,TANG Zhong-min,et al.Determination of Serum Uric Acid Level and its Clinical Significance in Non-alcoholic Fatty Liver Disease[J].Medical Information,2018,31(23):92.[doi:10.3969/j.issn.1006-1959.2018.07.029]
[2]刘 静.利拉鲁肽联合基础胰岛素对初诊2型糖尿病合并肥胖患者 血糖控制及体质量指数的影响[J].医学信息,2018,31(13):137.[doi:10.3969/j.issn.1006-1959.2018.13.040]
　LIU Jing.Effect of Liraglutide Combined with Basal Insulin on Blood Glucose Control and Body Mass Index in Newly Diagnosed Type 2 Diabetes Patients with Obesity[J].Medical Information,2018,31(23):137.[doi:10.3969/j.issn.1006-1959.2018.13.040]
[3]张熠霖,皇晓燕,赵滢滢,等.糖尿病胰岛病变及胰岛β细胞胰岛素分泌损伤检测的整合实验相关经验探讨[J].医学信息,2019,32(01):18.[doi:10.3969/j.issn.1006-1959.2019.01.006]
　ZHANG Yi-lin,HUANG Xiao-yan,ZHAO Ying-ying,et al.Experience in the Integration Experiment of Diabetic Islet Lesions and Islet β-cell Insulin Secretion Damage Detection[J].Medical Information,2019,32(23):18.[doi:10.3969/j.issn.1006-1959.2019.01.006]
[4]褚福行,李珊珊,李思琪,等.慢性牙周炎伴肥胖患者血清中IL-6、IL-18表达水平的研究[J].医学信息,2019,32(01):92.[doi:10.3969/j.issn.1006-1959.2019.01.028]
　CHU Fu-xing,LI Shan-shan,LI Si-qi,et al.Study on the Expression Levels of IL-6 and IL-18 in Serum of Patients with Chronic Periodontitis and Obesity[J].Medical Information,2019,32(23):92.[doi:10.3969/j.issn.1006-1959.2019.01.028]
[5]曾利文,陈 静,张 晔,等.多囊卵巢综合征患者的糖代谢特点分析[J].医学信息,2019,32(02):103.[doi:10.3969/j.issn.1006-1959.2019.02.029]
　ZENG Li-wen,CHEN Jing,ZHANG Ye,et al.Analysis of Characteristics of Glucose Metabolism in Patients with Polycystic Ovarian Syndrome[J].Medical Information,2019,32(23):103.[doi:10.3969/j.issn.1006-1959.2019.02.029]
[6]程晴晴,李元海,夏晓琼,等.超声联合神经刺激仪臂丛神经干精准阻滞在肥胖患者上肢手术中的应用[J].医学信息,2019,32(19):94.[doi:10.3969/j.issn.1006-1959.2019.19.028]
　CHENG Qing-qing,LI Yuan-hai,XIA Xiao-qiong,et al.Application of Ultrasound Combined with Neurostimulator for Brachial Plexus Nerve Block in Upper Limb Surgery in Obese Patients[J].Medical Information,2019,32(23):94.[doi:10.3969/j.issn.1006-1959.2019.19.028]
[7]李淑娟,王爱芹,杨学军,等.异常子宫出血患者子宫内膜病理类型与 临床特征的关系[J].医学信息,2019,32(14):104.[doi:10.3969/j.issn.1006-1959.2019.14.032]
　LI Shu-juan,WANG Ai-qin,YANG Xue-jun,et al.Relationship between Pathologic Type of Endometrium and Its Clinical Features in Patients with Abnormal Uterus Bleeding[J].Medical Information,2019,32(23):104.[doi:10.3969/j.issn.1006-1959.2019.14.032]
[8]牟 婷,张朝阳.胰岛素联合唑来膦酸治疗糖尿病骨质疏松症对患者血清指标的影响[J].医学信息,2019,32(22):135.[doi:10.3969/j.issn.1006-1959.2019.22.045]
　MU Ting,ZHANG Chao-yang.Effect of Insulin Combined with Zoledronic Acid on Serum Markers in Patients with Diabetic Osteoporosis[J].Medical Information,2019,32(23):135.[doi:10.3969/j.issn.1006-1959.2019.22.045]
[9]郑卫雷,王士雷.全身麻醉术中肺保护性通气对肥胖患者肺顺应性及氧合指数的影响[J].医学信息,2019,32(24):60.[doi:10.3969/j.issn.1006-1959.2019.24.019]
　ZHENG Wei-lei,WANG Shi-lei.Effect of Lung Protective Ventilation on General Lung Compliance and Oxygenation Index in Obese Patients[J].Medical Information,2019,32(23):60.[doi:10.3969/j.issn.1006-1959.2019.24.019]
[10]张晴晴,张瑞霞.Irisin的生理效应及其循环水平的影响因素[J].医学信息,2020,33(02):36.[doi:10.3969/j.issn.1006-1959.2020.02.010]
　ZHANG Qing-qing,ZHANG Rui-xia.The Physiological Effect of Irisin and the Influencing Factors of its Circulation Level[J].Medical Information,2020,33(23):36.[doi:10.3969/j.issn.1006-1959.2020.02.010]
[11]张 彤.利拉鲁肽联合胰岛素治疗新诊断肥胖2型糖尿病的临床疗效及安全性[J].医学信息,2022,35(05):159.[doi:10.3969/j.issn.1006-1959.2022.05.042]
　ZHANG Tong.Clinical Efficacy and Safety of Liraglutide Combined with Insulin in the Treatment of Newly Diagnosed Obese Type 2 Diabetes Mellitus[J].Medical Information,2022,35(23):159.[doi:10.3969/j.issn.1006-1959.2022.05.042]

更新日期/Last Update: 1900-01-01